Paperonium

Lung cancer · J Clin Oncol · 2022

The paper’s summary says 52.6% of 15 patients responded. Its own count: 7 of 15 (46.7%).

The same 15 patients46.7%Its results: 7 of 15The summary52.6%Where 52.6% comes from: 15 + 4 othersthe summary used this row10 of 1940%455055
The same 15 patients46.7%Its results: 7 of 15The summary52.6%Where 52.6% comes from: 15 + 4othersthe summary used this row10 of 1940%455055

Share of patients whose tumors shrank or vanished, depending on who is counted

The paper says

In a lung-cancer drug trial, the paper’s summary says 52.6% of the group it singles out responded (their tumors shrank or vanished): 15 patients whose tumors had a lot of c-Met, the protein one drug targets, and a change in a gene called EGFR.

Its own data show

With 15 patients, 7 responders is 46.7% and 8 is 53.3%; 52.6% is impossible. The paper’s results count 7 responders among those 15. 52.6% is 10 of 19, the results’ rate for all 19 patients with a lot of c-Met: the 15 plus 4 not in the EGFR-change group, 3 of whom responded.

A response rate is responders divided by patients counted, so it shifts with who is counted. This is the summary’s only figure for the group the paper says matters most. It reads as more than half; the real figure is just under half. These 15 still respond more often than all patients with the EGFR change: 32.1% (9 of 28).

“The summary” means the paper’s abstract: the short summary printed at its top, which is the part most readers see.

Read the paper →Full technical write-up →

Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein–Expressing Non–Small-Cell Lung Cancer · J Clin Oncol (2022) · doi:10.1200/JCO.22.00739